223127-49-9

Basic information

• Product Name: 4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID
• Synonyms: 4-(5-NITRO-2-PYRIDINYL)BENZENECARBOXYLIC ACID;4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID;4-(5-Nitropyridin-2-yl)benzoicacid95%;4-(6-(Trifluoromethyl)pyridin-2-yl)benzoic acid;4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID 95%
• CAS NO: 223127-49-9
• Molecular Formula: C₁₂H₈N₂O₄
• Molecular Weight: 244.2
• Mol File: 223127-49-9.mol

Chemical Properties

• Melting Point: 307-309°
• Boiling Point: 456.463 °C at 760 mmHg
• Flash Point: 229.861 °C
• Appearance: /
• Density: 1.417 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.644
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID(223127-49-9)
• EPA Substance Registry System: 4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID(223127-49-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 223127-49-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID is used as a potential pharmaceutical compound for its possible physiological and pharmacological activities, which are derived from the nitropyridin component. Its integration with benzoic acid may offer new avenues for drug development and therapeutic applications.
Used in Food Industry:
4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID is used as a preservative in food products, leveraging the antimicrobial properties of benzoic acid to extend shelf life and maintain food safety.
Used in Chemical Research:
4-(5-NITROPYRIDIN-2-YL)BENZOIC ACID is used as a subject of study in chemical research, where its unique combination of nitropyridin and benzoic acid may reveal new insights into the synthesis and properties of related compounds, potentially leading to the discovery of novel applications in various fields.

InChI:InChI=1/C12H8N2O4/c15-12(16)9-3-1-8(2-4-9)11-6-5-10(7-13-11)14(17)18/h1-7H,(H,15,16)

Upstream product

• 171364-80-0 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 586-76-5 4-Bromobenzoic acid 
• 223127-51-3 C₁₃H₁₀N₂O₄ 

Downstream Products

• 1337967-43-7 C₁₈H₂₁N₃O₃ 
• 1337967-44-8 C₂₅H₂₅FN₄O₄ 
• 1337967-45-9 C₂₅H₂₅FN₄O₄ 
• 1337967-46-0 C₂₅H₂₅FN₄O₄ 
• 1337967-47-1 C₂₆H₂₅F₃N₄O₅ 
• 1337967-48-2 C₂₆H₂₈N₄O₅ 
• 1337967-49-3 C₂₅H₂₄F₂N₄O₄ 
• 1337967-50-6 C₂₆H₂₈N₄O₄ 
• 1337967-51-7 C₂₄H₂₃FN₄O₄ 
• 1337967-52-8 C₂₄H₂₃FN₄O₄ 
• 1337967-53-9 C₂₄H₂₃FN₄O₄ 
• 1337967-54-0 C₂₅H₂₃F₃N₄O₅ 
• 1337967-55-1 C₂₅H₂₆N₄O₅ 
• 1337967-56-2 C₂₄H₂₂F₂N₄O₄ 

Relevant articles and documents

Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors

The diacylglycerol acyltransferase enzyme, DGAT1, presents itself as a potential target for obesity as this enzyme is dedicated to the final committed step in triglyceride biosynthesis. Biphenyl ureas, exemplified by compound 4, have been reported to be potent hDGAT1 inhibitors. We have synthesized and evaluated 2-pyridyl and 3-pyridyl containing biaryl ureas as hDGAT1 inhibitors. Our aim was to incorporate a heteroaryl scaffold within these molecules thereby improving the c Log P profile and making these compounds more drug-like. Compounds within this series exhibited potent hDGAT1 inhibition when evaluated using an in vitro enzymatic assay. Selected compounds were also subjected to an oral fat tolerance test in mice where the percent triglyceride reduction versus a vehicle control was evaluated. Of the studied heteroaryl analogs compound 44 exhibited an in vitro IC50 of 17 nM and a plasma triglyceride reduction of 79% along with a 12-fold improvement in solubility over the biphenyl urea compound 4.

N-acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.

N-Acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula Are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.